• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非胰岛素依赖型糖尿病患者血浆组织型纤溶酶原激活物(t-PA)和纤溶酶原激活物抑制剂-1(PAI-1)抗原浓度:治疗方式对纤溶的影响。

Plasma t-PA and PAl-1 antigen concentrations in non-insulin dependent diabetic patients: effects of treatment modality on fibrinolysis.

作者信息

Cho Y W, Yang D H, Oh D Y, Baick S H, Kim S K, Kim S J, Hong S Y

机构信息

Department of Internal Medicine, Soonchunhyang University College of Medicine, Chunan, Korea.

出版信息

Korean J Intern Med. 1992 Jul;7(2):81-6. doi: 10.3904/kjim.1992.7.2.81.

DOI:10.3904/kjim.1992.7.2.81
PMID:1306076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4532107/
Abstract

Basal plasma tissue type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAl-1) antigen levels were studied in 49 non-insulin dependent diabetic patients (23 men, 26 women: ages 51.3 +/- 14.9 years) and 16 age matched non-diabetic subjects (9 men, 7 women: ages 49.8 +/- 12.2 years) as a control group. Compared to a control group, the diabetic patients had a significantly higher mean t-PA antigen (5.15 +/- 3.02 vs 3.20 +/- 2.30 ng/ml) and PAl-1 antigen (35.89 +/- 18.59 vs 17.60 +/- 15.36 ng/ml) levels (p < 0.05). Plasma t-PA antigen level was not influenced by each treatment modality. There was a significant decrease of plasma PAl-1 antigen level after Metformin administration compared to that of before Metformin administration (39.74 +/- 19.39 vs 25.14 +/- 16.18 ng/ml) (p < 0.05), and the insulin-treated group showed a tendency for a decrease of plasma PAl-1 antigen levels after insulin administration but this did not reach statistical significance (29.93 +/- 15.37 vs 17.32 +/- 10.60 ng/ml). Sulfonylurea did not change both plasma t-PA and PAl-1 antigen levels. In conclusion, diabetic patients have high t-PA and PAl-1 antigen levels. Biguanide reduced plasma PAl-1 antigen levels, which might play some helpful role in the improvement of chronic complications in NIDDM.

摘要

对49例非胰岛素依赖型糖尿病患者(23例男性,26例女性;年龄51.3±14.9岁)和16例年龄匹配的非糖尿病受试者(9例男性,7例女性;年龄49.8±12.2岁)作为对照组,研究了基础血浆组织型纤溶酶原激活物(t-PA)和纤溶酶原激活物抑制剂1型(PAI-1)抗原水平。与对照组相比,糖尿病患者的平均t-PA抗原水平(5.15±3.02对3.20±2.30 ng/ml)和PAI-1抗原水平(35.89±18.59对17.60±15.36 ng/ml)显著更高(p<0.05)。血浆t-PA抗原水平不受每种治疗方式的影响。与服用二甲双胍前相比,服用二甲双胍后血浆PAI-1抗原水平显著降低(39.74±19.39对25.14±16.18 ng/ml)(p<0.05),胰岛素治疗组在胰岛素给药后血浆PAI-1抗原水平有下降趋势,但未达到统计学意义(29.93±15.37对17.32±10.60 ng/ml)。磺脲类药物未改变血浆t-PA和PAI-1抗原水平。总之,糖尿病患者具有较高的t-PA和PAI-1抗原水平。双胍类药物降低了血浆PAI-1抗原水平,这可能对改善非胰岛素依赖型糖尿病的慢性并发症起到一定的有益作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6299/4532107/5b8f25d59d6c/kjim-7-2-81-2f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6299/4532107/13e77be65915/kjim-7-2-81-2f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6299/4532107/5b8f25d59d6c/kjim-7-2-81-2f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6299/4532107/13e77be65915/kjim-7-2-81-2f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6299/4532107/5b8f25d59d6c/kjim-7-2-81-2f2.jpg

相似文献

1
Plasma t-PA and PAl-1 antigen concentrations in non-insulin dependent diabetic patients: effects of treatment modality on fibrinolysis.非胰岛素依赖型糖尿病患者血浆组织型纤溶酶原激活物(t-PA)和纤溶酶原激活物抑制剂-1(PAI-1)抗原浓度:治疗方式对纤溶的影响。
Korean J Intern Med. 1992 Jul;7(2):81-6. doi: 10.3904/kjim.1992.7.2.81.
2
Plasma t-PA and PAI-1 antigen concentrations in non-insulin dependent diabetic patients: implication for diabetic retinopathy.
Diabetes Res Clin Pract. 1994 Jan;22(2-3):123-8. doi: 10.1016/0168-8227(94)90045-0.
3
Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients.格列齐特诱导I型和II型糖尿病患者纤溶潜能增加。
Am J Med. 1991 Jun 24;90(6A):62S-66S. doi: 10.1016/0002-9343(91)90420-3.
4
Fibrinolysis and diabetic retinopathy in NIDDM.非胰岛素依赖型糖尿病中的纤维蛋白溶解与糖尿病视网膜病变
Diabetes Care. 1995 Dec;18(12):1577-81. doi: 10.2337/diacare.18.12.1577.
5
[Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)].非胰岛素依赖型糖尿病(NIDDM)患者血浆中的组织型纤溶酶原激活物及其抑制剂(PAI-1)
Nihon Ronen Igakkai Zasshi. 1990 Nov;27(6):699-705. doi: 10.3143/geriatrics.27.699.
6
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.曲格列酮对2型糖尿病患者以及瘦型和肥胖型正常受试者纤溶酶原激活物抑制剂1血药浓度的影响。
Diabetes. 2000 Apr;49(4):633-9. doi: 10.2337/diabetes.49.4.633.
7
No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids.在年轻女性摄入避孕类固醇之前及期间,胰岛素原和胰岛素对血浆1型纤溶酶原激活物抑制剂及组织型纤溶酶原激活物水平无影响。
Metabolism. 1996 Jul;45(7):833-7. doi: 10.1016/s0026-0495(96)90155-9.
8
Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction.2型糖尿病合并急性脑梗死患者的纤溶指标测定
Diabet Med. 1998 Nov;15(11):953-7. doi: 10.1002/(SICI)1096-9136(1998110)15:11<953::AID-DIA712>3.0.CO;2-6.
9
The effect of obesity on fibrinolytic activity and plasma lipoprotein (a) levels in patients with type 2 diabetes mellitus in Korea.肥胖对韩国2型糖尿病患者纤溶活性和血浆脂蛋白(a)水平的影响。
Diabetes Res Clin Pract. 1994 May;24(1):25-31. doi: 10.1016/0168-8227(94)90082-5.
10
The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus.新诊断2型糖尿病患者中纤溶酶原激活物抑制剂-1与胰岛素抵抗的关系
Diabet Med. 1993 Aug-Sep;10(7):638-42. doi: 10.1111/j.1464-5491.1993.tb00137.x.

引用本文的文献

1
Protection by metformin against severe Covid-19: An in-depth mechanistic analysis.二甲双胍对严重 COVID-19 的保护作用:深入的机制分析。
Diabetes Metab. 2022 Jul;48(4):101359. doi: 10.1016/j.diabet.2022.101359. Epub 2022 May 31.
2
Hyperglycemia Potentiates Prothrombotic Effect of Aldosterone in a Rat Arterial Thrombosis Model.高血糖增强醛固酮在大鼠动脉血栓模型中的促血栓形成作用。
Cells. 2021 Feb 22;10(2):471. doi: 10.3390/cells10020471.
3
Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies.

本文引用的文献

1
FIBRINOLYTIC EFFECT OF METFORMIN IN CORONARY-ARTERY DISEASE.二甲双胍对冠状动脉疾病的纤溶作用
Lancet. 1965 Aug 7;2(7406):256-9. doi: 10.1016/s0140-6736(65)92383-4.
2
Blood fibrinolytic activity in diabetes mellitus and its bearing on ischaemic heart disease and obesity.糖尿病患者的血液纤溶活性及其与缺血性心脏病和肥胖的关系。
Br Med J. 1963 Apr 6;1(5335):921-3. doi: 10.1136/bmj.1.5335.921.
3
Chronic lathyrism and atheromatosis in the rat. Protective effect of metformin.
Gerontology. 1980;26(4):188-99. doi: 10.1159/000212414.
纤溶酶原激活物抑制剂-1与2型糖尿病:观察性研究的系统评价和荟萃分析
Sci Rep. 2016 Jan 27;6:17714. doi: 10.1038/srep17714.
4
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.2型糖尿病患者使用二甲双胍时发生致命性和非致命性乳酸性酸中毒的风险。
Cochrane Database Syst Rev. 2010 Apr 14;2010(4):CD002967. doi: 10.1002/14651858.CD002967.pub4.
5
Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen.短期应用二甲双胍可改善代谢综合征且血糖正常的 2 型糖尿病患者一级亲属的心血管风险特征,而 C 反应蛋白或纤维蛋白原无变化。
Clinics (Sao Paulo). 2009 May;64(5):415-20. doi: 10.1590/s1807-59322009000500008.
4
Effects of diet and gliclazide on the haemostatic system of non-insulin-dependent diabetics.饮食与格列齐特对非胰岛素依赖型糖尿病患者止血系统的影响。
Br Med J (Clin Res Ed). 1981 Oct 17;283(6298):1018-20. doi: 10.1136/bmj.283.6298.1018.
5
Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells.牛内皮细胞产生的一种异常稳定的纤溶抑制剂的检测。
Proc Natl Acad Sci U S A. 1983 May;80(10):2956-60. doi: 10.1073/pnas.80.10.2956.
6
Effect of chlorpropamide and gliclazide on plasminogen activator activity in vascular walls in patients with maturity onset diabetes.氯磺丙脲和格列齐特对成年型糖尿病患者血管壁纤溶酶原激活物活性的影响。
Thromb Res. 1984 Jul 1;35(1):19-25. doi: 10.1016/0049-3848(84)90309-8.
7
Mechanisms of inhibition of tissue-type plasminogen activator in blood.血液中组织型纤溶酶原激活物的抑制机制。
Thromb Haemost. 1983 Oct 31;50(3):678.
8
Vascular fibrinolytic activity in long term treatment with second generation sulfonylurea compounds.第二代磺脲类化合物长期治疗中的血管纤溶活性
Acta Endocrinol Suppl (Copenh). 1980;239:53-5.
9
Effect of biguanides and atromid on fibrinolysis.双胍类药物和安妥明对纤维蛋白溶解的作用。
J Atheroscler Res. 1967 Mar-Apr;7(2):121-30. doi: 10.1016/s0368-1319(67)80074-7.
10
Fibrinolytic response to moderate exercise in young male diabetics and non-diabetics.年轻男性糖尿病患者和非糖尿病患者对适度运动的纤溶反应。
J Clin Pathol. 1969 Jan;22(1):32-5. doi: 10.1136/jcp.22.1.32.